Daniel W McVicar
Overview
Explore the profile of Daniel W McVicar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
4037
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Palczewski M, Kuschman H, Hoffman B, Kathiresan V, Yang H, Glynn S, et al.
Nat Commun
. 2025 Feb;
16(1):1732.
PMID: 39966373
DNA methylation at cytosine bases (5-methylcytosine, 5mC) is a heritable epigenetic mark regulating gene expression. While enzymes that metabolize 5mC are well-characterized, endogenous signaling molecules that regulate DNA methylation machinery...
2.
Ridnour L, Heinz W, Cheng R, Wink A, Kedei N, Pore M, et al.
Cancer Res Commun
. 2024 Oct;
4(10):2766-2782.
PMID: 39356141
This work identifies CD8-NOS2+COX2+ and CD8-NOS2-COX2+ unique cellular neighborhoods that drive the tumor immune spatial architecture of CD8+ T cells predictive of clinical outcome and can be targeted with clinically...
3.
Ridnour L, Cheng R, Kedei N, Somasundaram V, Bhattacharyya D, Basudhar D, et al.
JCI Insight
. 2024 Jun;
9(12).
PMID: 38912586
Immune therapy is the new frontier of cancer treatment. Therapeutic radiation is a known inducer of immune response and can be limited by immunosuppressive mediators including cyclooxygenase-2 (COX2) that is...
4.
Ridnour L, Cheng R, Heinz W, Pore M, Gonzalez A, Femino E, et al.
bioRxiv
. 2024 Jan;
PMID: 38187660
Multiple immunosuppressive mechanisms exist in the tumor microenvironment that drive poor outcomes and decrease treatment efficacy. The co-expression of NOS2 and COX2 is a strong predictor of poor prognosis in...
5.
Alsamraae M, Costanzo-Garvey D, Teply B, Boyle S, Sommerville G, Herbert Z, et al.
Cancer Lett
. 2023 Nov;
579:216468.
PMID: 37940068
Bone metastatic disease of prostate cancer (PCa) is incurable and progression in bone is largely dictated by tumor-stromal interactions in the bone microenvironment. We showed previously that bone neutrophils initially...
6.
Huang Y, Nahar S, Alam M, Hu S, McVicar D, Yang D
ACS Nano
. 2023 Oct;
17(20):19740-19752.
PMID: 37831945
Immunotherapy has revolutionized the field of cancer treatment through invigorating robust antitumor immune response. Here, we report the development of a peutic cine [consisting of high mobility group nucleosome-binding protein...
7.
Palmieri E, Holewinski R, McGinity C, Pierri C, Maio N, Weiss J, et al.
Nat Commun
. 2023 Aug;
14(1):5114.
PMID: 37607904
M1 macrophages enter a glycolytic state when endogenous nitric oxide (NO) reprograms mitochondrial metabolism by limiting aconitase 2 and pyruvate dehydrogenase (PDH) activity. Here, we provide evidence that NO targets...
8.
Weiss J, Palmieri E, Gonzalez-Cotto M, Bettencourt I, Megill E, Snyder N, et al.
Nat Metab
. 2023 Jun;
5(6):981-995.
PMID: 37308721
Itaconate, the product of the decarboxylation of cis-aconitate, regulates numerous biological processes. We and others have revealed itaconate as a regulator of fatty acid β-oxidation, generation of mitochondrial reactive oxygen...
9.
Cheng R, Ridnour L, Wink A, Gonzalez A, Femino E, Rittscher H, et al.
Cell Death Dis
. 2023 May;
14(5):319.
PMID: 37169743
A strong correlation between NOS2 and COX2 tumor expression and poor clinical outcomes in ER breast cancer has been established. However, the mechanisms of tumor induction of these enzymes are...
10.
Andrews C, McLean M, Hixon J, Pontejo S, Starr T, Malo C, et al.
Front Immunol
. 2023 May;
14:1021824.
PMID: 37153622
Mucosal delivery of IL-27 has been shown to have a therapeutic benefit in murine models of inflammatory bowel disease (IBD). The IL-27 effect was associated with phosphorylated STAT1 (pSTAT1), a...